A drug called ganciclovir is given to lung transplant patients to protect against a life-threatening virus that is common after transplantation. Ganciclovir reduces mortality due to the virus from 34 percent to between 3 and 6 percent. But between 5 percent and 10 percent of patients infected with the virus have strains that are resistant to the drug. A Loyola University Medical Center study found that such resistance may occur more frequently in cystic ...
via Medindia Health News
More READ 
Lake forest health and fitness http://ift.tt/1DUwvpG
No comments:
Post a Comment